Pearlie K. Epling‐Burnette

5.6k total citations · 1 hit paper
113 papers, 4.0k citations indexed

About

Pearlie K. Epling‐Burnette is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Pearlie K. Epling‐Burnette has authored 113 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 51 papers in Immunology and 38 papers in Genetics. Recurrent topics in Pearlie K. Epling‐Burnette's work include Acute Myeloid Leukemia Research (46 papers), Immune Cell Function and Interaction (31 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Pearlie K. Epling‐Burnette is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Immune Cell Function and Interaction (31 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Pearlie K. Epling‐Burnette collaborates with scholars based in United States, China and France. Pearlie K. Epling‐Burnette's co-authors include Thomas P. Loughran, Alan F. List, Julie Y. Djeu, Jin Hong Liu, Fanqi Bai, Sheng Wei, Richard Jove, Jeffrey S. Painter, Javier Pinilla‐Ibarz and Sheng Wei and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Pearlie K. Epling‐Burnette

108 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

2001 505 citations Pearlie K. Epling‐Burnette, Jin Hong Liu et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Pearlie K. Epling‐Burnette

Since Specialization

Citations

This map shows the geographic impact of Pearlie K. Epling‐Burnette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pearlie K. Epling‐Burnette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pearlie K. Epling‐Burnette more than expected).

Fields of papers citing papers by Pearlie K. Epling‐Burnette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pearlie K. Epling‐Burnette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pearlie K. Epling‐Burnette. The network helps show where Pearlie K. Epling‐Burnette may publish in the future.

Co-authorship network of co-authors of Pearlie K. Epling‐Burnette

This figure shows the co-authorship network connecting the top 25 collaborators of Pearlie K. Epling‐Burnette. A scholar is included among the top collaborators of Pearlie K. Epling‐Burnette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pearlie K. Epling‐Burnette. Pearlie K. Epling‐Burnette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms 2024 ·American Journal of Hematology ·(unknown), Lucia Mazzacurati, (unknown), (unknown), (unknown), Guolin Zhang, (unknown), Christelle Colin, Eric B. Haura, Andrew Kuykendall, Ling Zhang, Pearlie K. Epling‐Burnette, Gary W. Reuther	1
2	Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells 2023 ·JCI Insight ·(unknown), (unknown), Mario R. Fernandez, Chunying Yang, Lancia Darville, (unknown), John M. Koomen, Otto Phanstiel, (unknown), John E. Mullinax, Shari Pilon‐Thomas, Frederick L. Locke, Pearlie K. Epling‐Burnette, John L. Cleveland	15
3	Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting 2023 ·Blood Advances ·(unknown), Erika M. Gaglione, (unknown), John H. Herrick, (unknown), Inhye E. Ahn, Christopher Chiu, (unknown), Ida H. Hiemstra, Esther C.W. Breij, Jenny Chen, Edward B. Reilly, Pearlie K. Epling‐Burnette, (unknown), Clare Sun, Adrian Wiestner	27
4	Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms 2020 ·Frontiers in Immunology ·Vasundhara Sharma, Kenneth L. Wright, Pearlie K. Epling‐Burnette, Gary W. Reuther	8
5	The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN 2019 ·Blood Advances ·Lucia Mazzacurati, Robert J. Collins, (unknown), (unknown), (unknown), Ling Zhang, Matthew C. Stubbs, Pearlie K. Epling‐Burnette, Holly K. Koblish, Gary W. Reuther	21
6	Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study 2018 ·Blood ·Ling Zhang, Donald M. Stablein, Pearlie K. Epling‐Burnette, Alexandra M. Harrington, Lynn C. Moscinski, Steven H. Kroft, Amy E. DeZern, Tareq Al Baghdadi, Jane Jijun Liu, Matthew J. Walter, Rafael Bejar, Edward J. Gorak, Rami S. Komrokji, Gregory A. Abel, Bart L. Scott, Steven D. Gore, Mikkael A. Sekeres	3
7	T Regulatory Cell Subpopulations Associated with Recent Ultraviolet Radiation Exposure in a Skin Cancer Screening Cohort 2018 ·The Journal of Immunology ·(unknown), Rossybelle P. Amorrortu, (unknown), Shalaka Hampras, (unknown), Neil A. Fenske, Basil S. Cherpelis, (unknown), (unknown), Pearlie K. Epling‐Burnette, Dana E. Rollison	11
8	Efficacy of ALK5 inhibition in myelofibrosis 2017 ·JCI Insight ·(unknown), Matthias Bartenstein, Wanke Zhao, Wan‐Ting Ho, Ying Han, (unknown), Adam W. Mailloux, Ling Zhang, Xuefeng Wang, (unknown), Kith Pradhan, Franck Rapaport, Huaquan Wang, Zonghong Shao, Xiubao Ren, Ulrich Steidl, Ross L. Levine, Zhizhuang Joe Zhao, Amit Verma, Pearlie K. Epling‐Burnette	34
9	Relative Lymphocytosis Is Associated with Improved Outcome in Myelofibrosis and May Account for the Favorable Prognosis of the Calr mutation 2017 ·Blood ·Andrew Kuykendall, Chetasi Talati, Pearlie K. Epling‐Burnette, Najla Al Ali, Eric Padron, Kendra Sweet, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji	2
10	The inflammatory microenvironment in MDS 2015 ·Cellular and Molecular Life Sciences ·Lili Yang, (unknown), Erika A. Eksioglu, Pearlie K. Epling‐Burnette, Wei Sheng	58
11	A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction 2014 ·Haematologica ·Rami S. Komrokji, Adam W. Mailloux, (unknown), Mikkael A. Sekeres, Ronald Paquette, William J. Fulp, Chiharu Sugimori, (unknown), Jaroslaw P. Maciejewski, Alan F. List, Pearlie K. Epling‐Burnette	36
12	Emerging immunosuppressive drugs in myelodysplastic syndromes 2012 ·Expert Opinion on Emerging Drugs ·Pearlie K. Epling‐Burnette, (unknown), Sheng Wei, Alan F. List	7
13	Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion 2012 ·Oncogene ·Sheng Wei, X Chen, Kathy L. McGraw, (unknown), Rami S. Komrokji, Justine Clark, Gisela Cáceres, (unknown), Lubomir Sokol, Jeffrey E. Lancet, Nicole Fortenbery, Jianwei Zhou, Erika A. Eksioglu, David A. Sallman, (unknown), Pearlie K. Epling‐Burnette, J Y Djeu, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Alan F. List	74
14	Immune Dysregulation in Myelodysplastic Syndrome 2010 ·Hematology Reports ·Chiharu Sugimori, Alan F. List, Pearlie K. Epling‐Burnette	16
15	Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome 2009 ·Leukemia ·JianXiang Zou, Dana E. Rollison, David Boulware, (unknown), Elaine M. Sloand, Loretta Pfannes, Jörg J. Goronzy, Fanqi Bai, Jeffrey S. Painter, Sheng Wei, Denise Cosgrove, Alan F. List, Pearlie K. Epling‐Burnette	45
16	Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy 2009 ·Leukemia ·Satu Mustjoki, Marja Ekblom, T. Petteri Arstila, Ingunn Dybedal, Pearlie K. Epling‐Burnette, François Guilhot, Henrik Hjorth‐Hansen, Martin Höglund, Panu E. Kovanen, (unknown), Jane L. Liesveld, Ronald Paquette, Javier Pinilla‐Ibarz, Auvo Rauhala, Neil P. Shah, Bengt Simonsson, Marjatta Sinisalo, Juan Luis Steegmann, Leif Stenke, Kimmo Porkka	229
17	Advancements in the molecular pathogenesis of myelodysplastic syndrome 2009 ·Current Opinion in Hematology ·Pearlie K. Epling‐Burnette, Alan F. List	32
18	Human neutrophils utilize a Rac/Cdc42-dependent MAPK pathway to direct intracellular granule mobilization toward ingested microbial pathogens 2003 ·Blood ·Bin Zhong, Kun Jiang, Danielle L. Gilvary, Pearlie K. Epling‐Burnette, (unknown), Jinhong Liu, Rosalind J. Jackson, Elizabeth Hong‐Geller, Sheng Wei	42
19	Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression breakdown → 2001 ·Journal of Clinical Investigation ·Pearlie K. Epling‐Burnette, Jin Hong Liu, Robyn Catlett-Falcone, James Turkson, Marc M. Oshiro, Ravi Kothapalli, Yongxiang Li, Ju‐Ming Wang, Hsin‐Fang Yang‐Yen, James G. Karras, Richard Jove, Thomas P. Loughran	505
20	Expression of interleukin‐2 receptor γ on human monocytes: characterization of lineage specific post‐translational modifications 1995 ·European Journal of Immunology ·Pearlie K. Epling‐Burnette, (unknown), Jin Hong Liu, Federica Pericle, (unknown), Sarah M. Russell, W J Leonard, Julie Y. Djeu	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact